Wave Life Sciences develops RNA medicines using a stereopure oligonucleotide chemistry platform designed for greater precision and control than conventional mixtures. Its PRISM platform supports programs across genetic diseases, with modalities that can silence, restore, or otherwise modulate RNA. The company partners and advances candidates aimed at neurological, hepatic, and other genetically defined conditions where RNA-targeted drugs can address the underlying molecular defect.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 8.7 | — | -50.5 | — |
| Q3 2025 | 7.6 | — | -53.9 | — |
| Q4 2025 | 17.3 | — | -53.2 | — |
| Q1 2026 | 38.3 | — | -26.1 | — |
| Q2 2026 | 2.3 | -73.9% | -69.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hertz Global Holdings, Inc. (HTZ), Tiptree Inc. (TIPT), Lightwave Logic, Inc. (LWLG), Gladstone Commercial Corporation (GOOD), Stratasys Ltd. (SSYS), Nuvectis Pharma, Inc. (NVCT)